Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer

By sjmartinez • September 12, 2024

Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Consolidation ALK Tyrosine Kinase Inhibitors versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer. J Thorac Oncol. 2024 Sep 9:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Epub ahead of print. PMID: 39260522.

Tags: Cedars Sinai DoM, Hematology/Oncology, Publications

Temporal Changes in Quality of Life in Patients with alcohol-associated Acute Pancreatitis

Kadi T, Zheng Y, Papachristou GI, Buxbaum JL, Pisegna JR, Pandol SJ, Adeniran E, Rothenberger S, Jeon CY, Yadav D. Temporal Changes in Quality of[...]

Uptake, Geographic Access, and Outcomes of Transcatheter Mitral Valve Repair in the United States

Watanabe A, Ueyama HA, Miyamoto Y, Gotanda H, Kaneko T, Latib A, Kolte D, Baron SJ, Secemsky E, Laham RJ, Tsugawa Y, Kuno T. Uptake,[...]

Ferumoxytol-Enhanced Cardiovascular Magnetic Resonance Imaging: Applications and Technical Advances

Nguyen KL, Loke YH, Li JM, Bedayat A, Yang HJ, Xie Y, Christodoulou AG, Li D, Zhong X, Finn JP. Ferumoxytol-Enhanced Cardiovascular Magnetic Resonance Imaging:[...]